Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.38 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227155 | 0.86 | RARG (0.37) | RARGRORC | |
| SCHEMBL5225253 | 0.84 | RARG (0.36) | RARGRORCPGR | |
| SCHEMBL5227542 | 0.83 | NAPRT (0.33) | RARGRORC | |
| SCHEMBL509125 | 0.81 | P2RX3 (0.35) | RARGRORCPGR | |
| SCHEMBL509057 | 0.79 | PGR (0.41) | RARGRORCPTGDR2PGR | |
| SCHEMBL509348 | 0.73 | P2RX3 (0.35) | RARGRORCPTGDR2PGR | |
| SCHEMBL5227964 | 0.72 | PTGDR2 (0.42) | RARGRORCPTGDR2PGR | |
| SCHEMBL508919 | 0.72 | RARG (0.33) | RARGRORCPGR | |
| SCHEMBL5229047 | 0.71 | KCNH2 (0.36) | PTGDR2PGR | |
| SCHEMBL5227620 | 0.70 | PGR (0.41) | PTGDR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | F10 2267/4885RARG 3182/4885RORC 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.